Drug Search Results
More Filters [+]

Trimebutine

Alternative Names: trimebutine, trimebutina, trimebutin
Latest Update: 2024-04-02
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TLR2 Inhibitor,TLR4 Inhibitor,TLR7 Inhibitor,TLR8 Inhibitor,TLR9 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Argentina | Bangladesh | Brazil | Bulgaria | Canada | Chile | China | Colombia | Dominican Republic | Ecuador | Egypt | France | Greece | Hong Kong | India | Italy | Korea | Lebanon | Mexico | Morocco | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Spain | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Kingdom | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Huahai Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trimebutine

Countries in Clinic: Russia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Cholecystitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GIB-01-02-2023

P1

Recruiting

Cholecystitis

2024-12-31

21%

Recent News Events

Date

Type

Title